Goldman G, Kahn P J, Kashtan H, Stadler J, Wiznitzer T
Department of Surgery A, Ichilov Hospital, Tel-Aviv Medical Center, Israel.
Surg Gynecol Obstet. 1988 May;166(5):447-50.
In a retrospective study, 153 male patients who underwent surgical treatment of the colon and rectum presented with complaints indicating obstruction of the prostate gland and clear indications for preoperative administration of alpha-blockers. Between the years 1982 and 1984, the alpha-blocker phenoxybenzamine hydrochloride (PB-HCl) was prohibited from use by the Ministry of Health because of suspicions of its carcinogenic properties. This enabled a comparative study between two groups of patients. Seventy-five patients (group 2a1) were prohibited from receiving PB-HCl. Urinary retention occurred in 54.7 per cent and urinary tract infection in 65.3 per cent. Seventy-eight patients (group 2a2) were administered PB-HCl. In this group of patients, urinary retention occurred in 19.2 per cent and urinary tract infection in 15.4 per cent. Forty-one patients with urinary retention of group 2a1 who were not administered PB-HCl were compared with 50 patients with urinary retention (group 3) who received PB-HCl. Spontaneous relief was observed in 21.9 and 76.0 per cent, respectively. PB-HCl was shown to be extremely effective, both as a preventative and therapeutic agent, when complaints indicating the prostate gland are present in patients undergoing surgical treatment of the colon and rectum.
在一项回顾性研究中，153例接受结肠和直肠手术治疗的男性患者出现了提示前列腺梗阻的症状，且有术前使用α受体阻滞剂的明确指征。在1982年至1984年期间，由于怀疑其致癌特性，卫生部禁止使用α受体阻滞剂盐酸酚苄明（PB-HCl）。这使得能够对两组患者进行比较研究。75例患者（2a1组）被禁止使用PB-HCl。尿潴留发生率为54.7%，尿路感染发生率为65.3%。78例患者（2a2组）使用了PB-HCl。在这组患者中，尿潴留发生率为19.2%，尿路感染发生率为15.4%。将2a1组未使用PB-HCl的41例尿潴留患者与接受PB-HCl的50例尿潴留患者（3组）进行比较。分别观察到21.9%和76.0%的患者症状自发缓解。当接受结肠和直肠手术治疗的患者出现提示前列腺的症状时，PB-HCl作为预防和治疗药物显示出极其有效。
